Stephen V. Liu, MD - A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
Go online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Describe the mechanisms of action and rationale for use of novel therapies for SCLC, including immune checkpoint inhibitors, PARP inhibitors, transcription inhibitors, and other investigational agents and combinations, Discuss key clinical trials assessing different new therapies for SCLC, Evaluate the latest available clinical trial data regarding standard as well as novel/emerging therapeutic approaches for SCLC, Integrate novel therapies into treatment plans for patients with SCLC either in the context of routine clinical practice or clinical trial participation.
Publication date: Available online 20 November 2019Source: Journal of Advanced ResearchAuthor(s): Sohail Mumtaz, Pradeep Bhartiya, Neha Kaushik, Manish Adhikari, Pradeep Lamichhane, Su-Jae Lee, Nagendra Kumar Kaushik, Eun Ha ChoiAbstractOver the past few decades, microwave (MW) radiation has been widely used, and its biological effects have been extensively investigated. However, the effect of MW radiation on human skin biology is not well understood. We study the effects of pulsed high-power microwaves (HPMs) on melanoma (G361 and SK-Mel-31) and normal human dermal fibroblast (NHDF) cells. A pulsed power generator (Chundo...
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 16 December 2019, highlighting Roche data presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, from 10th - 14th December.
Journal of Medicinal Food, Ahead of Print.
CONCLUSIONS Our data demonstrate an oncogenic role of miR-652 in uveal melanoma, showing that miR-652 may be a useful biomarker for prediction of prognosis for patients with uveal melanoma. PMID: 31740654 [PubMed - in process]
This study identified correlates of good screening performance for three common cancers, while weighing them against the backdrop of existing knowledge, to enable policy makers and healthcare providers focus appropriately to close the gaps that exist in cancer screening in our locale. Study design: Cross-sectional design. Setting: Tertiary health facility. Participants: Workers at Delta State University Teaching Hospital, Nigeria. Results: Females had significantly better knowledge of cervical cancer, p
Employing multiple artificial intelligence (AI) algorithms to attack a task...Read more on AuntMinnie.comRelated Reading: Practical Considerations of AI: Part 6 -- Ready, fire, aim Deep-learning algorithm bolsters lung cancer detection AI needs robust clinical evaluation in healthcare Deep-learning model characterizes PET/CT findings Can AI find brain hemorrhage as well as radiologists?
Future Oncology, Ahead of Print.
Future Oncology, Ahead of Print.
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
A better understanding of the existing disparities in PrEP discontinuation may help identify which populations are most at risk.AIDS